Wilfried Reichardt

Principal Investigator

Advanced Molecular Imaging Research (AMIR)
Dept. of Radiology Medical Physics
Medical Center University of Freiburg

Killianstraße 5a
79106 Freiburg

Current position

Group Leader AMIR-Preclinical Imaging Research Center, Department of Radiology Medical Physics

Academic training

1996 - 2004Study of Medicine, Saarland University Homburg

Advanced academic qualifications

2004Dissertation in Medicine, Saarland University, Medical Faculty, Homburg

Postgraduate positions

Since 2006Deputy-Head of Molecular Imaging Research and Postdoctoral Researcher; Dept. of Radiology Medical Physics, Medical Center University of Freiburg
2004 - 2006Assistant Physician; Dept. of Radiology Medical Physics, Medical Center University of Freiburg

Miscellaneous (Honors, Awards)

2010ISMRM Grant
2008SMRM Travel Stipend, ISMRM Annual Meeting 2008 Toronto
1999 - 2004Scholarship of the German Academic Foundation
1999-2000Personal Stipend and Speaker of the graduate students
by the SFB 399, “Molekularpathologie der Proliferation”

Publications listed in PubMed®

Publications (based on CRC1479 funding)

Hafner P, Keller SJ, Chen X, Alrawashdeh A, Jumaa H, Nollmann FI, Besson S, Kemming J, Gorka O, Das T, Appiah B, Lehmann A, Li M, Apostolova P, Bengsch B, Zeiser R, Tholen S, Schilling O, Groß O, Vlachos A, Wittel UA, von Elverfeldt D, Reichardt W, Boerries M, Andrieux G, Heynen GJ, Fichtner-Feigl S, Hannibal L, Ruess DA. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Signal Transduct Target Ther. 2026 Jan 16;11(1):33. doi: 10.1038/s41392-025-02563-7.
Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.
Reichardt W, Gewalt T, Hafner P, Keller SJ, Chen X, Alrawashdeh A, Li Y, Besson S, Fichtner-Feigl S, von Elverfeldt D, Jumaa H, Ruess DA. 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. J Magn Reson Imaging. 2025 Apr;61(4):1996-2008. doi: 10.1002/jmri.29589. Epub 2024 Aug 27.

de Maissin H, Groß PR, Mohiuddin O, Weigt M, Nagel L, Herzog M, Wang Z, Willing R, Reichardt W, Pichotka M, Heß L, Reinheckel T, Jessen HJ, Zeiser R, Bock M, von Elverfeldt D, Zaitsev M, Korchak S, Glöggler S, Hövener JB, Chekmenev EY, Schilling F, Knecht S, Schmidt AB. In Vivo Metabolic Imaging of [1-13C]Pyruvate-d3 Hyperpolarized By Reversible Exchange With Parahydrogen. Angew Chem Int Ed Engl. 2023 Jul 13:e202306654. doi: 10.1002/anie.202306654. Epub ahead of print.

Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, Federkiel Y, Huang H, Hoefflin R, Adlesic M, Witt C, Hoffmann DJ, Metzger P, Lindemann RK, Zenke FT, Schell C, Boerries M, von Elverfeldt D, Reichardt W, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight. 2022 Dec 22;7(24):e156087. doi: 10.1172/jci.insight.156087.